ANDA 90472, held by Zydus Pharms. Aripiprazole.
As of Nov 16, 2026, ANDA 90472 (Aripiprazole), held by Zydus Pharms, was first approved by FDA on Jan 7, 2019, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 7, 2019 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Discontinued |
| Aug 7, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 7, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 7, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 7, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters